• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[四环素类药物在牙周疾病治疗中的临床应用]

[Clinical use of tetracyclines in the treatment of periodontal diseases].

作者信息

Bokor-Bratić M, Brkanić T

机构信息

Klinika za stomatologiju, Medicinski fakultet, Novi Sad, Hajduk Veljkova.

出版信息

Med Pregl. 2000 May-Jun;53(5-6):266-71.

PMID:11089368
Abstract

INTRODUCTION

There are a number of chemically different tetracycline homologues. The older group of tetracyclines, which was introduced in the 1950-60s, includes tetracycline, oxytetracycline, chlortetracycline and demeclocycline. The newer group of tetracyclines includes doxycycline, methacycline and minocycline.

PHARMACOKINETICS

Elevated concentration of tetracycline in gingival fluid with respect to blood levels was an unexpected phenomenon. Patients given 250 mg every 6 hours had average crevicular fluid concentrations between 4 to 8 g/ml and blood concentrations between 2 to 2.5 g/ml after 48 hours. The levels in crevicular fluid and blood of volunteers who received 250 mg every 12 hours were 2 to 4 g/ml and 0.3 to 1.4 g/ml respectively after 48 hours. The concentration of doxycycline in gingival fluid after administration of 200 mg/1st day and then 100 mg/day achieved average level of 6 g/ml. Minocycline, a semisynthetic derivate of tetracycline, has shown to yield gingival fluid levels 5 times as high as serum levels after administration of 100 mg every 12 hours.

MECHANISMS OF ACTION

Tetracycline and its derivates demonstrate high in vitro activity against most periodontal bacteria, including Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Eikenella corrodens, Wolinella recta and Fusobacterium nucleatum. The study of in vitro susceptibility of these 6 bacterial strains showed that, in regard to blood level, minimal inhibitory concentration is higher and it is the concentration of the drug that can be expected in gingival fluid following oral administration of 100 mg per day (doxycycline) (Table 1). The anti-inflammatory effect of tetracyclines was demonstrated histologically not only by reducing the size of the infiltrated connective tissue, but qualitative changes were also observed. Golub and associates have presented evidence that tetracyclines inhibit collagenase activity in gingival fluid and in tissue cultures. Therapeutic concentrations of tetracycline inhibit chemotaxis, phagocytosis and random migration of neutrophils in vitro.

ADVERSE EFFECTS

Great amounts of tetracyclines cause gastrointestinal disorders, nausea, vomiting and diarrhea. Tetracyclines suppress activity of the enzymes in the bowel and pancreas. During longlasting administration they can damage the liver and kidneys. Tetracyclines can cause photo-sensibilization. They make deposits with calcium in bones, specially during prenatal period and during growth, so they can cause permanent teeth discoloration and hypoplasia.

INTERACTIONS

The most important interaction is with penicillin. These two kinds of antibiotics antagonize and decrease the therapeutic effect of each other, so their administration at the same time should be avoided. A significant interaction occurs between tetracyclines and metal ions. This interaction often has been observed in conjunction with use of various antacids. Tetracyclines can also influence the production and absorption of vitamin K. Nephrotoxicity has been reported when tetracyclines have been administrated in conjunction with methoxyflurane.

INDICATIONS

Doxycycline, due to its advantages over tetracycline (Table 2), is indicated in treating destructive periodontal diseases including: juvenile periodontitis and refractory marginal periodontitis. Doxycycline therapy may be used for acute periodontal abscess and if the conditions are accompanied by general symptoms. Prophylactic application is recommended for implant placement procedures including membranes in guided tissue regeneration.

RESULTS OF CLINICAL STUDY

ORAL APPLICATION: In spite of great number of published investigations this paper presents only the results of placebo-controlled, double-blind studies. There is evidence that therapy in localized juvenile periodontitis should eliminate Actinobacillus actinomycetemcomitans, since 95% of patients harbored this bacteria. (ABSTRACT TRUNCATED)

摘要

引言

有多种化学结构不同的四环素同系物。20世纪50至60年代引入的较老一代四环素包括四环素、土霉素、金霉素和地美环素。较新的一代四环素包括多西环素、美他环素和米诺环素。

药代动力学

相对于血液水平,龈沟液中四环素浓度升高是一种意外现象。每6小时服用250毫克的患者,48小时后龈沟液平均浓度在4至8微克/毫升之间,血液浓度在2至2.5微克/毫升之间。每12小时服用250毫克的志愿者,48小时后龈沟液和血液中的水平分别为2至4微克/毫升和0.3至1.4微克/毫升。服用200毫克/第一天然后100毫克/天的多西环素后,龈沟液中的浓度平均达到6微克/毫升。米诺环素是四环素的半合成衍生物,每12小时服用100毫克后,龈沟液水平显示为血清水平的5倍。

作用机制

四环素及其衍生物对大多数牙周细菌具有高体外活性,包括伴放线放线杆菌、牙龈卟啉单胞菌、中间普氏菌、腐蚀埃肯菌、直肠沃林菌和具核梭杆菌。对这6种细菌菌株的体外药敏研究表明,就血液水平而言,最小抑菌浓度较高,而这是每天口服100毫克(多西环素)后龈沟液中可预期的药物浓度(表1)。四环素的抗炎作用在组织学上不仅表现为减少浸润结缔组织的大小,还观察到了质的变化。戈卢布及其同事提供的证据表明,四环素可抑制龈沟液和组织培养中的胶原酶活性。四环素的治疗浓度在体外可抑制中性粒细胞的趋化性、吞噬作用和随机迁移。

不良反应

大量四环素会导致胃肠道紊乱、恶心、呕吐和腹泻。四环素会抑制肠道和胰腺中酶的活性。长期给药期间,它们会损害肝脏和肾脏。四环素会引起光敏反应。它们会在骨骼中与钙结合沉积,特别是在孕期和生长期间,因此会导致恒牙变色和发育不全。

相互作用

最重要的相互作用是与青霉素。这两种抗生素相互拮抗,降低彼此的治疗效果,因此应避免同时给药。四环素与金属离子之间会发生显著相互作用。这种相互作用经常在与各种抗酸剂联合使用时观察到。四环素还会影响维生素K的产生和吸收。四环素与甲氧氟烷联合使用时曾有肾毒性报道。

适应症

由于多西环素相对于四环素具有优势(表2),它适用于治疗破坏性牙周疾病,包括:青少年牙周炎和难治性边缘性牙周炎。多西环素疗法可用于急性牙周脓肿以及伴有全身症状的情况。对于包括引导组织再生中的膜在内的种植体植入手术,建议进行预防性应用。

临床研究结果

口服应用:尽管已发表了大量研究,但本文仅呈现了安慰剂对照、双盲研究的结果。有证据表明,局限性青少年牙周炎的治疗应清除伴放线放线杆菌,因为95%的患者携带这种细菌。(摘要截断)

相似文献

1
[Clinical use of tetracyclines in the treatment of periodontal diseases].[四环素类药物在牙周疾病治疗中的临床应用]
Med Pregl. 2000 May-Jun;53(5-6):266-71.
2
Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article.不同牙周疾病中四环素对龈沟液中胶原酶的抑制作用及细胞来源。一篇综述文章。
J Periodontol. 1993 Feb;64(2):82-8. doi: 10.1902/jop.1993.64.2.82.
3
Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems.四环素可抑制组织胶原酶。摄入低剂量及局部给药系统的效果。
J Periodontol. 1985 Nov;56(11 Suppl):93-7. doi: 10.1902/jop.1985.56.11s.93.
4
Tetracycline inhibition identifies the cellular sources of collagenase in gingival crevicular fluid in different forms of periodontal diseases.四环素抑制作用确定了不同形式牙周疾病龈沟液中胶原酶的细胞来源。
Drugs Exp Clin Res. 1992;18(3):99-104.
5
The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.四环素治疗牙周疾病的非抗菌特性。
Curr Opin Periodontol. 1994:111-8.
6
Current status of systemic antibiotic usage in destructive periodontal disease.侵袭性牙周炎全身应用抗生素的现状
J Periodontol. 1993 Aug;64(8 Suppl):760-71. doi: 10.1902/jop.1993.64.8s.760.
7
Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva.血浆、龈沟液和唾液中3种四环素的浓度。
J Clin Periodontol. 2000 Jan;27(1):53-60. doi: 10.1034/j.1600-051x.2000.027001053.x.
8
Effect of azithromycin, as an adjunct to nonsurgical periodontal treatment, on microbiological parameters and gingival crevicular fluid biomarkers in generalized aggressive periodontitis.阿奇霉素辅助非手术牙周治疗对广泛性侵袭性牙周炎患者微生物参数和龈沟液生物标志物的影响。
J Periodontal Res. 2012 Dec;47(6):729-39. doi: 10.1111/j.1600-0765.2012.01488.x. Epub 2012 May 9.
9
Adjunctive subantimicrobial dose doxycycline: effect on clinical parameters and gingival crevicular fluid transforming growth factor-beta levels in severe, generalized chronic periodontitis.辅助性亚抗菌剂量强力霉素:对重度广泛性慢性牙周炎临床参数及龈沟液转化生长因子-β水平的影响
J Clin Periodontol. 2005 Mar;32(3):244-53. doi: 10.1111/j.1600-051X.2005.00663.x.
10
Microbiological response of localized sites with recurrent periodontitis in maintenance patients treated with tetracycline fibers.接受四环素纤维治疗的维持期复发性牙周炎患者局部部位的微生物学反应
J Periodontol. 1999 Aug;70(8):861-8. doi: 10.1902/jop.1999.70.8.861.

引用本文的文献

1
Drug release kinetics and biological properties of a novel local drug carrier system.一种新型局部药物载体系统的药物释放动力学及生物学特性
Dent Res J (Isfahan). 2021 Nov 22;18:94. doi: 10.4103/1735-3327.330875. eCollection 2021.
2
Pharmacokinetic drug-drug interaction and their implication in clinical management.药代动力学药物相互作用及其在临床管理中的意义。
J Res Med Sci. 2013 Jul;18(7):601-10.
3
Novel antibacterial nanofibrous PLLA scaffolds.新型抗菌纳米纤维 PLLA 支架。
J Control Release. 2010 Sep 15;146(3):363-9. doi: 10.1016/j.jconrel.2010.05.035. Epub 2010 Jun 4.